Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zandelisib and Tazemetostat in Relapsed or Refractory Follicular Lymphoma
NCT05604417Phase 2Withdrawn
- Start
- Jan 2023
- Primary completion
- Dec 2024
01
Overview
A Phase 2 trial of zandelisib in follicular lymphoma (FL). Planned start Jan 2023; status: withdrawn.
02
Drugs
zandelisib
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05604417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05604417.